Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.028 AUD | +3.70% | -3.45% | +16.67% |
Apr. 08 | AdAlta Explores Cancer Immunotherapies Joint Venture for Western Market | MT |
Feb. 26 | AdAlta Limited Reports Earnings Results for the Half Year Ended December 31, 2023 | CI |
Sales 2022 | 2.75M 1.77M | Sales 2023 | 3.47M 2.22M | Capitalization | 8.8M 5.64M |
---|---|---|---|---|---|
Net income 2022 | -6M -3.85M | Net income 2023 | -4M -2.56M | EV / Sales 2022 | 4.47 x |
Net cash position 2022 | 4.66M 2.99M | Net cash position 2023 | 776K 497K | EV / Sales 2023 | 2.31 x |
P/E ratio 2022 |
-2.48
x | P/E ratio 2023 |
-1.57
x | Employees | 10 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 63.48% |
1 day | +3.70% | ||
1 week | -3.45% | ||
Current month | +3.70% | ||
1 month | +12.00% | ||
3 months | +16.67% | ||
6 months | +14.29% | ||
Current year | +16.67% |
Managers | Title | Age | Since |
---|---|---|---|
Timothy Oldham
CEO | Chief Executive Officer | - | 19-10-13 |
Mick Foley
CTO | Chief Tech/Sci/R&D Officer | - | - |
Dallas Hartman
COO | Chief Operating Officer | - | 17-10-08 |
Members of the board | Title | Age | Since |
---|---|---|---|
Robert Peach
BRD | Director/Board Member | 68 | 16-11-13 |
Paul MacLeman
CHM | Chairman | 58 | 15-04-15 |
Timothy Oldham
CEO | Chief Executive Officer | - | 19-10-13 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-19 | 0.028 | +3.70% | 2 964 789 |
24-04-18 | 0.027 | 0.00% | 168,996 |
24-04-17 | 0.027 | 0.00% | 1,585,725 |
24-04-16 | 0.027 | 0.00% | 1,171,487 |
24-04-15 | 0.027 | -6.90% | 1,046,925 |
Delayed Quote Australian S.E., April 19, 2024 at 02:10 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+16.67% | 9.14M | |
-3.30% | 102B | |
+1.79% | 96.07B | |
-1.19% | 21.66B | |
-18.35% | 20.77B | |
-7.87% | 18.53B | |
-40.31% | 16.91B | |
-26.84% | 13.79B | |
+0.59% | 13.33B | |
+20.86% | 10.94B |
- Stock Market
- Equities
- 1AD Stock